3 results on '"Yang, James C. -H."'
Number of results to display per page
Search Results
2. Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
- Author
-
Paik, Paul K., primary, Felip, Enriqueta, additional, Veillon, Remi, additional, Sakai, Hiroshi, additional, Cortot, Alexis B., additional, Garassino, Marina C., additional, Mazieres, Julien, additional, Viteri, Santiago, additional, Senellart, Helene, additional, Van Meerbeeck, Jan, additional, Raskin, Jo, additional, Reinmuth, Niels, additional, Conte, Pierfranco, additional, Kowalski, Dariusz, additional, Cho, Byoung Chul, additional, Patel, Jyoti D., additional, Horn, Leora, additional, Griesinger, Frank, additional, Han, Ji-Youn, additional, Kim, Young-Chul, additional, Chang, Gee-Chen, additional, Tsai, Chen-Liang, additional, Yang, James C.-H., additional, Chen, Yuh-Min, additional, Smit, Egbert F., additional, van der Wekken, Anthonie J., additional, Kato, Terufumi, additional, Juraeva, Dilafruz, additional, Stroh, Christopher, additional, Bruns, Rolf, additional, Straub, Josef, additional, Johne, Andreas, additional, Scheele, Jürgen, additional, Heymach, John V., additional, and Le, Xiuning, additional
- Published
- 2020
- Full Text
- View/download PDF
3. Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC.
- Author
-
Cho BC, Lu S, Felip E, Spira AI, Girard N, Lee JS, Lee SH, Ostapenko Y, Danchaivijitr P, Liu B, Alip A, Korbenfeld E, Mourão Dias J, Besse B, Lee KH, Xiong H, How SH, Cheng Y, Chang GC, Yoshioka H, Yang JC, Thomas M, Nguyen D, Ou SI, Mukhedkar S, Prabhash K, D'Arcangelo M, Alatorre-Alexander J, Vázquez Limón JC, Alves S, Stroyakovskiy D, Peregudova M, Şendur MAN, Yazici O, Califano R, Gutiérrez Calderón V, de Marinis F, Passaro A, Kim SW, Gadgeel SM, Xie J, Sun T, Martinez M, Ennis M, Fennema E, Daksh M, Millington D, Leconte I, Iwasawa R, Lorenzini P, Baig M, Shah S, Bauml JM, Shreeve SM, Sethi S, Knoblauch RE, and Hayashi H
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Acrylamides therapeutic use, Aniline Compounds therapeutic use, Antineoplastic Agents, Immunological administration & dosage, Antineoplastic Agents, Immunological adverse effects, ErbB Receptors genetics, ErbB Receptors antagonists & inhibitors, Kaplan-Meier Estimate, Mutation, Progression-Free Survival, Protein Kinase Inhibitors administration & dosage, Protein Kinase Inhibitors adverse effects, Quinolines therapeutic use, Treatment Outcome, Antibodies, Bispecific, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antineoplastic Combined Chemotherapy Protocols adverse effects, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung genetics, Carcinoma, Non-Small-Cell Lung mortality, Carcinoma, Non-Small-Cell Lung pathology, Lung Neoplasms drug therapy, Lung Neoplasms genetics, Lung Neoplasms mortality, Lung Neoplasms pathology, Morpholines administration & dosage, Morpholines adverse effects, Pyrimidines administration & dosage, Pyrimidines adverse effects, Pyrazoles administration & dosage, Pyrazoles adverse effects
- Abstract
Background: Amivantamab plus lazertinib (amivantamab-lazertinib) has shown clinically meaningful and durable antitumor activity in patients with previously untreated or osimertinib-pretreated EGFR (epidermal growth factor receptor)-mutated advanced non-small-cell lung cancer (NSCLC)., Methods: In a phase 3, international, randomized trial, we assigned, in a 2:2:1 ratio, patients with previously untreated EGFR -mutated (exon 19 deletion or L858R), locally advanced or metastatic NSCLC to receive amivantamab-lazertinib (in an open-label fashion), osimertinib (in a blinded fashion), or lazertinib (in a blinded fashion, to assess the contribution of treatment components). The primary end point was progression-free survival in the amivantamab-lazertinib group as compared with the osimertinib group, as assessed by blinded independent central review., Results: Overall, 1074 patients underwent randomization (429 to amivantamab-lazertinib, 429 to osimertinib, and 216 to lazertinib). The median progression-free survival was significantly longer in the amivantamab-lazertinib group than in the osimertinib group (23.7 vs. 16.6 months; hazard ratio for disease progression or death, 0.70; 95% confidence interval [CI], 0.58 to 0.85; P<0.001). An objective response was observed in 86% of the patients (95% CI, 83 to 89) in the amivantamab-lazertinib group and in 85% of those (95% CI, 81 to 88) in the osimertinib group; among patients with a confirmed response (336 in the amivantamab-lazertinib group and 314 in the osimertinib group), the median response duration was 25.8 months (95% CI, 20.1 to could not be estimated) and 16.8 months (95% CI, 14.8 to 18.5), respectively. In a planned interim overall survival analysis of amivantamab-lazertinib as compared with osimertinib, the hazard ratio for death was 0.80 (95% CI, 0.61 to 1.05). Predominant adverse events were EGFR -related toxic effects. The incidence of discontinuation of all agents due to treatment-related adverse events was 10% with amivantamab-lazertinib and 3% with osimertinib., Conclusions: Amivantamab-lazertinib showed superior efficacy to osimertinib as first-line treatment in EGFR -mutated advanced NSCLC. (Funded by Janssen Research and Development; MARIPOSA ClinicalTrials.gov number, NCT04487080.)., (Copyright © 2024 Massachusetts Medical Society.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.